Skip to content
Sonic
AI
Sonic
AI
Home
Discover
Ask Sonic
Projects
Use with Claude or ChatGPT
Show me around
Request source or feature
Preparing for the Pandemic We Haven't Seen Yet w/ Dr. Dan Barouch & Kris Brown, Vector Sciences, Sonic AI
Home
/
CareTalk
/
Preparing for the Pandemic We Haven't Seen Yet w/ Dr. Dan Barouch & Kris Brown, Vector Sciences
CareTalk
Notify me
•
Jul 1, 2026
•
34:11
Interview
Preparing for the Pandemic We Haven't Seen Yet w/ Dr. Dan Barouch & Kris Brown, Vector Sciences
From
Care Talk
David Williams
(Host, Care Talk)
•
David E. Williams
(Host)
•
Kristopher Brown
(Guest)
•
Dr. Dan Barouch
(Guest)
Get the full transcript next time CareTalk releases an episode
Summary, key quotes, top claims, and the searchable transcript — emailed automatically. No card needed.
Sign up
Executive Summary
Vector Sciences is developing the Riovax platform, a rhesus adenovirus vector vaccine, to provide a superior alternative to existing technologies like mRNA and first-generation adenoviral vaccines.
The platform's key advantages include enhanced safety by avoiding proteins linked to thrombosis, improved efficacy due to no pre-existing human immunity, and superior logistics with no cold chain and needle-free mucosal delivery.
A primary focus is on inducing mucosal immunity via nasal spray, which aims to block viral transmission at the point of entry—a significant limitation of current intramuscular respiratory vaccines.
The company is initially targeting the large influenza market, citing preclinical data showing superiority over existing vaccines and next-gen mRNA candidates, with broader applications in biodefense and pandemic preparedness.
Continue your research
Keep pulling the thread on Dr. Dan Barouch & Kris Brown.
Vaccine Platform Diversification
Mucosal vs. Systemic Immunity
12
quotes
Transcript
Key Arguments
Analysis
Quotes & Entities
12
Related
Loading transcript...
Processed Jul 1, 2026
Daily intelligence brief →
yt-dlp + mlx-whisper + Gemini